The anticoagulants are very important in the prevention of blood clotting as well as the diagnosis of various blood clotting disorders in patients. They also make it possible for the hemostatic status of an individual to be accessed 1. However, the effectiveness of anticoagulants varies greatly and hence the need to make a comparison between one anticoagulant against another. This study therefore aims at making a comparison between a recently developed anticoagulant against warfarin 2.
To make a comparison of newly discovered drug X against warfarin, both being anticoagulants.
Null hypothesis: there is no significant difference between drug X and warfarin in terms of blood anticoagulation capabilities.
Alternate hypothesis: there is a significant difference between drug X and warfarin in terms of blood anticoagulation capabilities.
The clinical samples from the study subject might be stable, and homogenous as compared to those collected from other centers like emergency departments.
In this study, an evaluation of the specificity and sensitivity of blood clotting drugs in terms of prothrombin time and the partial thromboplastin time of drug X against warfarin. A convenient sample of thirty-five patients will be randomly samples for use in this study. The inclusion criteria will be based on patients being of eighteen years and above, both men and women. They will be required to fill an informed consent form of acceptance to participate.
This will be a diagnostic and observational study which will be carried at San Loius hospital in Turkey. Initially, ethical clearance will be sought from the University ethical committee. The study subjects will be drawn from those admitted in this hospital for the period between September to November 2017 and suffering from deep vein thrombosis. Twenty of them will be treated using daily doses of 5, 10, 15mL of warfarin while the other ten will be treated using similar doses of drug X. another group of ten patients will be used as a control group, having no known blood clotting problems in order to test the normal ranges of the tests to be performed.
Sample collection and testing
The blood samples will be collected after every two hours of each drug administration per group, as well as two hours before the next dose is given. The prothrombin time for the blood samples will be done using the STA neoplastine reagent CI plus while the partial thromboplastin time will be done using STA cephascreen and processing done of STA-R coagulation analyzer equipment 3.
While this research will be based on the two anticoagulant drugs, other variables such as gender, age and other health conditions that might affect the variables in this research will not be measured.
The plasma concentrations will be expressed in terms of means and standard deviations. The results will be presented in form of scatter graphs, tables and charts to determine the differences in the anticoagulation properties of drug X against warfarin. Overall data will be analyzed using the SPSS version 22 statistical software.
- Sankaranarayanan R, J Fox D. Are Some Anticoagulants More Equal Than Others?-Evaluating the Role of Novel Oral Anticoagulants in AF Ablation. Current cardiology reviews. 2016 Nov 1;12(4):330-5.
- Ashburner JM, Go AS, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. Journal of the American Geriatrics Society. 2017 Jan 1;65(1):35-41.
- Colombini MP, Derogis PB, Aranda VF, Guerra JC, Hamerschlak N, Mangueira CL. Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study. Thrombosis Journal. 2017 Aug 15;15(1):21.
- Asthana HS, Bhushan B. Statistics for social sciences (with SPSS applications). PHI Learning Pvt. Ltd.; 2016 Jun 7.